


Application No. 10/647,191  
Amendment dated October 19, 2005  
Reply to Office Action of September 21, 2005

Docket No.: 58289(72021)

pharmaceutical compositions comprising said compounds. The present election is made solely to comply with the Office Action and should not be construed as a surrender of any subject matter of the application. Applicant reserves the right to file divisional application(s) on the non-elected claims.

Responsive to the species election, Applicants elect compound 15 provided in Table I on page 64 of the specification. Compound 15 has the structure:



Claims 1-3, 7-10, 12-21, 25, 29, 31-35, and 45-47 read on the elected species.

As the restriction requirement is understood, the Examiner will review the claims and disclosure to determine the scope of the independent invention encompassing the elected compound. In the interest of facilitating the scope of the independent invention, Applicants offer a proposed scope of the invention and a listing of claims which read on the proposed scope.

Proposed Scope of the Invention:

Compounds of Claim 1, in which:

R represents:

heterocycloalkyl, which is optionally substituted;

R<sub>1</sub> represents:

(i) hydrogen, hydroxy, halogen, amino, cyano, nitro, C<sub>1</sub>-C<sub>2</sub>haloalkyl or C<sub>1</sub>-C<sub>2</sub> haloalkoxy;

Application No. 10/647,191  
Amendment dated October 19, 2005  
Reply to Office Action of September 21, 2005

Docket No.: 58289(72021)

- (ii) C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>2</sub>-C<sub>4</sub>alkenyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>cycloalkyl)C<sub>1</sub>-C<sub>2</sub>alkyl, or mono- or di-C<sub>1</sub>-C<sub>6</sub>alkylamino R<sub>2</sub> is optionally substituted C<sub>1</sub>-C<sub>7</sub> alkyl or optionally substituted C<sub>2</sub>-C<sub>7</sub> alkenyl; or
- (iii) phenylC<sub>0</sub>-C<sub>4</sub>carbhydryl or (5- or 6-membered heteroaryl)C<sub>0</sub>-C<sub>4</sub>carbhydryl, each of which is optionally substituted;

R<sub>3</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl;

R<sub>4</sub> represents:

- (ii) optionally substituted arylC<sub>0</sub>-C<sub>2</sub>alkyl having 1 ring or 2 fused rings; or
- (iii) optionally substituted arylC<sub>1</sub>-C<sub>2</sub>alkyl, wherein the aryl portion is fused to a 5- to 7-membered saturated or partially unsaturated ring having 0, 1 or 2 ring atoms independently chosen from N, O and S, with remaining ring atoms being carbon;

R<sub>5</sub> and R<sub>6</sub> are independently chosen from hydrogen and C<sub>1</sub>-C<sub>6</sub>alkyl; and

Ar represents:

- (i) optionally substituted aryl having 1 ring or 2 fused or pendant rings; or
- (ii) optionally substituted phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring having 0, 1 or 2 ring atoms independently chosen from N, O and S, with remaining ring atoms being carbon.

Claims 1-10, 12-21, 23, 25, 29, 31-34, and 45-47 read on the proposed scope of the invention.

Applicants request rejoinder of the method claims of commensurate scope to the composition of matter claims upon allowance of claims directed to the elected invention.

Early consideration of the application and claims as amended is earnestly solicited.

Although it is not believed that any additional fees are needed to consider this submission, the Examiner is hereby authorized to charge our deposit account no. 04-1105 should any fee be deemed necessary.

Application No. 10/647,191  
Amendment dated October 19, 2005  
Reply to Office Action of September 21, 2005

Docket No.: 58289(72021)

In view of the above amendment, applicant believes the pending application  
is in condition for allowance.

Dated: October 20, 2005

Respectfully submitted,

By 

John B. Alexander, Ph.D.  
Registration No.: 48,399  
EDWARDS & ANGELL, LLP  
P.O. Box 55874  
Boston, Massachusetts 02205  
(617) 439-4444  
Attorneys/Agents For Applicant